Clinical Trials for Mesothelioma Patients—A Study of Avastin Plus Pemetrexed-Cisplatin: Inclusion and Exclusion Criteria

Read about the inclusion and exclusion criteria for a current clinical trial about the use of Avastin Plus Pemetrexed-Cisplatin Decitabine and FR901228 for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At the current time, the study is only being conducted in Belgium and France.

Malignant, histologically proved, non resectable pleural Mesothelioma
In case of pleural effusion, a talc pleurodesis, although not recommended, is allowed in accordance with current local practice, at the time of diagnostic thorascopy, with inclusion CT scan performed after pleurodesis.
ECOG Performance status 0-2
Mesothelioma with only pleural effusion without uni- or bidimensionally measurable disease will be eligible (adapted RECIST criteria)
At least 18 years of age, less than 76 years of age
Radiation therapy of thoracocentis tract (3 x 7Gy) performed before beginning medical study treatment, and the interval between thoracoscopic procedure and radiation will not exceed 28 days

Prior chemotherapy
Brain metastasis
History of cerebral vascular accident (CVA) or transient ischemic attack

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.